Licensing

FDA Renews and Expands its Portfolio of Simcyp Simulator (PBPK) Licenses

November 14, 2017

Increased Use of Physiologically-based Pharmacokinetic (PBPK) Modeling and Simulation (M&S) is a Priority in Both the Prescription Drug User Fee Act and Generic Drug User Fee Amendments Certara®, the global leader in model-informed drug development and regulatory science, today announced that the US Food and Drug Administration (FDA) has greatly expanded its use of Certara’s […]

Ionis Licenses Novel Antisense Drug for the Treatment of Centronuclear Myopathy to Dynacure

November 9, 2017

CARLSBAD, Calif. and STRASBOURG, France, Nov. 9, 2017 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and Dynacure announced today that Dynacure has licensed IONIS-DNM2-2.5Rx (Dyn101), a Generation 2.5 antisense drug targeting dynamin 2 for the treatment of centronuclear myopathy (CNM), for which Ionis earned a $5 million license fee in the form of Dynacure equity. […]

Ionis Licenses Novel Antisense Drug for the Treatment of Centronuclear Myopathy to Dynacure

November 9, 2017

Carlsbad, Calif. and Strasbourg, France, November 9, 2017 – Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and Dynacure announced today that Dynacure has licensed IONIS-DNM2-2.5Rx (Dyn101), a Generation 2.5 antisense drug targeting dynamin 2 for the treatment of centronuclear myopathy (CNM), for which Ionis earned a $5 million license fee in the form of Dynacure equity. Dynacure […]

VBL Therapeutics and NanoCarrier Co., Ltd. Sign Exclusive Agreement for VB-111 in Japan

November 6, 2017

TEL AVIV, Israel, Nov. 06, 2017 (GLOBE NEWSWIRE) — VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announces an exclusive license agreement with NanoCarrier Co., Ltd. (TSE Mothers:4571) for the development, commercialization, and supply of ofranergene obadenovec (“VB-111”) in Japan. VBL Therapeutics (VBLT) […]

Novartis Files CAR-T in Lymphoma, Sets Up Rivalry With Gilead

November 2, 2017

Novartis has filed for a second US use of its Kymriah CAR-T therapy, in a move that will put it in competition with Gilead’s more recently approved rival.   The new US filing announced this week means Novartis is pursuing approval in relapsed/refractory diffuse large B-cell (r/r DLBCL) lymphoma patients ineligible for autologous stem cell […]

Kogenix Licenses Gene Therapy for Prevention of Age-Related Dementia and Alzheimer’s

October 31, 2017

BOSTON, October 31, 2017 (Newswire.com) – In a paper published today in Nature’s Molecular Psychiatry (https://www.nature.com/mp/journal/vaop/ncurrent/full/mp2017211a.html), scientists from Universitat Autonoma de Barcelona (UAB) and the Vall d’Hebron Research Institute showed for the first time cognitive improvements in old animals that were treated at younger age with secreted alpha Klotho (s-KL) gene therapy. These study results […]

Daiichi Sankyo and Glycotope Announce Option Agreement for Antibody Drug Conjugate Strategic Collaboration and Licensing

October 30, 2017

Tokyo, Japan, Basking Ridge, NJ, and Berlin, Germany – (October 30, 2017) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Glycotope GmbH (hereafter, Glycotope) have signed an option agreement for future strategic collaboration and licensing to develop an antibody drug conjugate (ADC) by combining Daiichi Sankyo’s proprietary ADC technology with Glycotope’s investigational tumor-associated TA-MUC1 […]

Navidea Signs Letter of Intent to Sublicense NAV4694 Worldwide Development Rights

October 27, 2017

DUBLIN, Ohio–(BUSINESS WIRE)–Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the execution of a non-binding letter of intent with Cerveau Technologies, Inc. (Cerveau) sublicensing the worldwide rights to conduct research using NAV4694, a beta-amyloid imaging agent being evaluated as an aid in the […]

Visterra Announces Research Collaboration, Exclusive License, and Option Agreement for Infectious Diseases with Vir Biotechnology

October 18, 2017

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Visterra, Inc. today announced that it has entered into a research collaboration, exclusive license, and option agreement with Vir Biotechnology, Inc. to develop and commercialize select programs for infectious diseases derived from Visterra’s Hierotope® platform technology. The strategic collaboration will combine Visterra’s novel platform for designing and engineering antibody-based biological medicines against unique […]

Visterra Announces Research Collaboration, Exclusive License, and Option Agreement for Infectious Diseases with Vir Biotechnology

October 18, 2017

Cambridge, MA – October 18, 2017 – Visterra, Inc. today announced that it has entered into a research collaboration, exclusive license, and option agreement with Vir Biotechnology, Inc. to develop and commercialize select programs for infectious diseases derived from Visterra’s Hierotope® platform technology. The strategic collaboration will combine Visterra’s novel platform for designing and engineering […]

Syndax Expands Pipeline with Exclusive Worldwide License to Allergan’s Portfolio of Menin-MLL Inhibitors

October 17, 2017

WALTHAM, Mass., Oct. 17, 2017 /PRNewswire/ — Syndax Pharmaceuticals, Inc. (“Syndax,” the “Company” or “we”) (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing entinostat and SNDX-6352 in multiple cancer indications, today announced that it has entered into an exclusive worldwide license agreement with Vitae Pharmaceuticals, Inc., a subsidiary of Allergan plc, for a portfolio of […]

Acerus Announces Licensing of NATESTO® in South East Asian Countries

October 17, 2017

TORONTO–(BUSINESS WIRE)–Acerus Pharmaceuticals Corporation (TSX:ASP) today announced the signing of an agreement granting Eu Hwa Pte LTD. (“EU”) the exclusive right to market NATESTO® in Thailand, Malaysia/Brunei, Singapore, Vietnam, Philippines, Hong Kong/Macau and one other small South East Asian country. EU is a subsidiary of one of Taiwan’s largest pharmaceutical companies, which has more than […]

INmune Bio Licenses INB03, a First-in Class Innate Immune System Check-Point Inhibitor that Targets Myeloid Derived Suppressor Cells in Cancer

October 10, 2017

LA JOLLA, CA–(Marketwired – Oct 10, 2017) – INmune Bio, Inc., a cancer immunotherapy company focused on developing therapies that harness the patient’s innate immune system to attack their cancer, announces that it has licensed INB03, a novel innate immune system check-point inhibitor that targets Myeloid Derived Suppressor Cells, from Xencor, Inc. Myeloid Derived Suppressor […]

INmune Bio Licenses Technology to Deplete Myeloid Derived Suppressor Cells of the Innate Immune System in Patients with Cancer

October 9, 2017

LA JOLLA, CA–(Marketwired – Oct 9, 2017) – INmune Bio, Inc., a cancer immunotherapy company focused on developing therapies that harness the patient’s innate immune system to attack their cancer, announced they obtained a license to intellectual property developed by Dr. Nikola Vujanovic, Professor Emeritus of Pathology and Immunology Department of Pathology, and Dr. Lazar […]

Neon Therapeutics Enters License Agreement with the Netherlands Cancer Institute for Neoantigen-based T Cell Therapeutics

October 5, 2017

CAMBRIDGE, Mass. & AMSTERDAM–(BUSINESS WIRE)–Neon Therapeutics, an immuno-oncology company developing neoantigen-based therapeutic vaccines and T cell therapies to treat cancer, today announced that the company has entered into an exclusive license agreement with the Netherlands Cancer Institute (NKI) for technology to be utilized in Neon Therapeutics’ personalized neoantigen T cell therapy program, NEO-PTC-01.   Under […]

XOMA Announces Multiple New License Agreements for Proprietary Phage Display Libraries

October 5, 2017

BERKELEY, Calif., Oct. 04, 2017 (GLOBE NEWSWIRE) — XOMA Corporation (Nasdaq:XOMA), a pioneer in the discovery, development and licensing of therapeutic antibodies, today announced it has entered into new non-exclusive license agreements with three different companies, Tizona Therapeutics, Inc., Torch Biosciences, Inc., and LakePharma, for use of XOMA’s proprietary phage display libraries for antibody discovery. […]

Breckenridge Pharmaceutical, Inc. and Impopharma, Inc. enter into licensing agreement

October 2, 2017

BOCA RATON, Fla., Sept. 29, 2017 /PRNewswire/ — Breckenridge Pharmaceutical, Inc. announced today that it has entered into a licensing agreement with Impopharma, Inc. to commercialize a generic version of a leading corticosteroid product with generic sales in excess of $25M. Impopharma is the manufacturer of the ANDA, which will be marketed exclusively by Breckenridge […]

Mallinckrodt Licenses Inhaled Xenon Gas Therapy Development Product

October 2, 2017

STAINES-UPON-THAMES, United Kingdom, Oct. 2, 2017 /PRNewswire/ — Mallinckrodt plc (NYSE:MNK) today announced it has entered into a licensing agreement for development and commercialization of NeuroproteXeon’s investigational, pharmaceutical-grade xenon gas for inhalation therapy being evaluated to improve survival and functional outcomes for patients resuscitated after a cardiac arrest. If approved, xenon gas for inhalation will […]

Provention Bio Announces Licensing Agreements with Janssen for Two Clinical-Stage Immunology Assets

September 21, 2017

LEBANON, N.J., Sept. 21, 2017 /PRNewswire/ — Provention Bio, Inc., a clinical stage biopharmaceutical company dedicated to sourcing, developing and commercializing novel therapeutics aimed at intercepting and preventing immune-mediated diseases, announced today that it has entered into agreements with Janssen Pharmaceutica NV and Janssen Sciences Ireland UC [Janssen] to in-license two clinical-stage assets, PRV-6527 (JNJ-40346527), […]

Nicox announces licensing agreement with Eyevance for commercialization of ZERVIATETM in the United States

September 21, 2017

Nicox to receive $6 million upfront payment and up to an additional $42.5 million in future milestones, plus 8-15% in tiered royalties Eyevance targeting U.S. launch of ZERVIATETM (cetirizine ophthalmic solution) 0.24% in late 2018   September 21, 2017 – release at 7:30 am CET Sophia Antipolis, France     Nicox S.A. (Euronext Paris: FR0013018124, […]

Provention Bio Announces Licensing Agreements with Janssen for Two Clinical-Stage Immunology Assets

September 21, 2017

Lebanon, NJ, September 21, 2017 – Provention Bio, Inc., a clinical stage biopharmaceutical company dedicated to sourcing, developing and commercializing novel therapeutics aimed at intercepting and preventing immune-mediated diseases, announced today that it has entered into agreements with Janssen Pharmaceutica NV and Janssen Sciences Ireland UC [Janssen] to in-license two clinical-stage assets, PRV-6527 (JNJ-40346527), an […]

ThromboGenics NV : ThromboGenics Regains Global Rights to JETREA® (ocriplasmin)

September 18, 2017

Leuven, Belgium, 18th September, 2017 – ThromboGenics NV (Euronext Brussels: THR), a biotechnology company developing novel treatments for retinal disorders, with a focus on diabetic eye disease, announced today that it will regain full global rights to JETREA® from Alcon, a Novartis company, based on a mutual agreement that the unique characteristics of JETREA make […]

Bristol-Myers Squibb and Halozyme Enter Global Collaboration and License Agreement for ENHANZE Technology

September 14, 2017

NEW YORK & SAN DIEGO–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) and Halozyme Therapeutics, Inc. (NASDAQ:HALO) today announced a global collaboration and license agreement to develop subcutaneously administered Bristol-Myers Squibb immuno-oncology medicines using Halozyme’s ENHANZE® drug-delivery technology. “We are excited to partner with Halozyme to pursue potential new approaches to how our medicines are delivered to patients,” […]

Onxeo Grants Exclusive Worldwide License of Validive® Developed for the Treatment of Oral Severe Mucositis to Monopar Therapeutics

September 13, 2017

PARIS, Sept. 13, 2017 (GLOBE NEWSWIRE) — Onxeo S.A. (Euronext Paris:ONXEO) (NASDAQ Copenhagen:ONXEO), (“Onxeo” or the “Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, today announces the Company has granted a global exclusive license of its product Validive® (clonidine mucoadhesive buccal […]

Avadel Pharmaceuticals Enters into Exclusive License Agreement for Noctiva™

September 6, 2017

DUBLIN, Ireland, Sept. 05, 2017 (GLOBE NEWSWIRE) — Avadel Pharmaceuticals plc (NASDAQ:AVDL) (“Avadel”), today announced that it has entered into a license agreement with Serenity Pharmaceuticals, LLC (“Serenity”). The agreement grants Avadel the sole right to commercialize and further develop Noctiva in the United States and Canada. Noctiva is a proprietary low-dose formulation of desmopressin […]

MEI Pharma Announces Exclusive License Agreement with Presage Biosciences for Voruciclib, An Oral, Selective CDK Inhibitor

September 6, 2017

SAN DIEGO and SEATTLE, Sept. 5, 2017 /PRNewswire/ — MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today announced that it has entered into a license agreement with Presage Biosciences, Inc. for voruciclib, a clinical-stage, oral and selective cyclin-dependent kinase (CDK) inhibitor. Under the terms […]

Palatin Technologies Announces Signing of Licensing Agreement with Fosun Pharma Rights to Bremelanotide in China and Other Selected Territories

September 6, 2017

CRANBURY, NJ, Sept. 6, 2017 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN; “Palatin”) announced today that it has entered into a collaboration and license agreement with Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd., a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”), for exclusive rights to develop and commercialize bremelanotide for female […]

FEEDBACK